- Home
- ADPT vs TRMD Comparison
ADPT vs TRMD Comparison
Compare ADPT & TRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- TRMD
- Stock Information
- Founded
- ADPT 2009
- TRMD 1889
- Country
- ADPT United States
- TRMD United Kingdom
- Employees
- ADPT N/A
- TRMD N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- TRMD Marine Transportation
- Sector
- ADPT Health Care
- TRMD Consumer Discretionary
- Exchange
- ADPT Nasdaq
- TRMD Nasdaq
- Market Cap
- ADPT 1.4B
- TRMD 1.7B
- IPO Year
- ADPT 2019
- TRMD N/A
- Fundamental
- Price
- ADPT $9.55
- TRMD $16.75
- Analyst Decision
- ADPT Buy
- TRMD Buy
- Analyst Count
- ADPT 6
- TRMD 1
- Target Price
- ADPT $9.83
- TRMD $23.00
- AVG Volume (30 Days)
- ADPT 1.8M
- TRMD 827.3K
- Earning Date
- ADPT 05-01-2025
- TRMD 05-08-2025
- Dividend Yield
- ADPT N/A
- TRMD 23.93%
- EPS Growth
- ADPT N/A
- TRMD N/A
- EPS
- ADPT N/A
- TRMD 4.74
- Revenue
- ADPT $189,527,000.00
- TRMD $1,444,200,000.00
- Revenue This Year
- ADPT $25.00
- TRMD N/A
- Revenue Next Year
- ADPT $20.38
- TRMD N/A
- P/E Ratio
- ADPT N/A
- TRMD $3.53
- Revenue Growth
- ADPT 8.61
- TRMD N/A
- 52 Week Low
- ADPT $2.99
- TRMD $13.60
- 52 Week High
- ADPT $10.28
- TRMD $40.47
- Technical
- Relative Strength Index (RSI)
- ADPT 60.50
- TRMD 49.17
- Support Level
- ADPT $8.50
- TRMD $15.79
- Resistance Level
- ADPT $9.69
- TRMD $17.51
- Average True Range (ATR)
- ADPT 0.42
- TRMD 0.45
- MACD
- ADPT -0.00
- TRMD -0.16
- Stochastic Oscillator
- ADPT 81.40
- TRMD 36.92
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About TRMD TORM plc
TORM PLC operates as a shipping company. The company owns and operates product tankers. It is engaged in the transportation of refined oil products The company transports clean petroleum products including gasoline, jet fuel, naphtha, and diesel oil, as well as other clean products. Its segments include the Tanker segment, and Marine Engineering segment. The company derives maximum revenue from Tanker segment.